Nathan Caffo - Net Worth and Insider Trading

Nathan Caffo Net Worth

The estimated net worth of Nathan Caffo is at least $75,600 dollars as of 2026-09-09. Nathan Caffo is the Chief Business Officer of Candel Therapeutics Inc and owns about 6,000 shares of Candel Therapeutics Inc (CADL) stock worth over $75,600. Details can be seen in Nathan Caffo's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Nathan Caffo has not made any transactions after 2021-07-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Nathan Caffo

To

Are these stocks worth buying? — GuruFocus analysis for each holding

Nathan Caffo Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Nathan Caffo owns 2 companies in total, including ALX Oncology Holdings Inc (ALXO) , and Candel Therapeutics Inc (CADL) .

Click here to see the complete history of Nathan Caffo’s form 4 insider trades.

Insider Ownership Summary of Nathan Caffo

Ticker Company Transaction Date Type of Owner
ALXO ALX Oncology Holdings Inc 2020-07-16 Chief Business Officer
CADL Candel Therapeutics Inc 2021-07-29 Chief Business Officer

Nathan Caffo Latest Holdings Summary

Nathan Caffo currently owns a total of 1 stock. Nathan Caffo owns 6,000 shares of Candel Therapeutics Inc (CADL) as of July 29, 2021, with a value of $75,600.

Latest Holdings of Nathan Caffo

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CADL Candel Therapeutics Inc 2021-07-29 6,000 12.60 75,600

Holding Weightings of Nathan Caffo


Nathan Caffo Form 4 Trading Tracker

According to the SEC Form 4 filings, Nathan Caffo has made a total of 0 transactions in Candel Therapeutics Inc (CADL) over the past 5 years. The most-recent trade in Candel Therapeutics Inc is the acquisition of 6,000 shares on July 29, 2021, which cost Nathan Caffo around $48,000.

Insider Trading History of Nathan Caffo

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Nathan Caffo Trading Performance

GuruFocus tracks the stock performance after each of Nathan Caffo's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Nathan Caffo is 53.84%. GuruFocus also compares Nathan Caffo's trading performance to market benchmark return within the same time period. The performance of stocks bought by Nathan Caffo within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Nathan Caffo's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Nathan Caffo

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 9.59 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 7.55 LIMIT LIMIT LIMIT LIMIT LIMIT

Get the full picture on these stocks
See GF Score, valuation, financials, and warning signs for every stock Nathan Caffo owns.
View CADL Analysis

Nathan Caffo Ownership Network

Ownership Network List of Nathan Caffo

No Data

Ownership Network Relation of Nathan Caffo

Insider Network Chart


Nathan Caffo Owned Company Details

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

Nathan Caffo is the Chief Business Officer of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include SVP & FINANCE AND CAO Shelly Pinto , director & 10 percent owner Jason Lettmann , and Chief Dev & Operating Officer Jeff E. Knight .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, Nathan Caffo made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 11,524 shares made by Shelly Pinto , a net purchase of 75,310 shares made by Jason Lettmann , and a net purchase of 3,184,713 shares made by Goodman Corey S .

In summary, during the past 3 months, insiders sold 4,207 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 0 shares, with a net sale of 4,207 shares. During the past 18 months, 28,447 shares of ALX Oncology Holdings Inc (ALXO) were sold and 3,351,946 shares were bought by its insiders, resulting in a net purchase of 3,323,499 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

ALX Oncology Holdings Inc Insider Transactions

No Available Data

Nathan Caffo Mailing Address

Above is the net worth, insider trading, and ownership report for Nathan Caffo. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Nathan Caffo's mailing address is: Burlingame Ca 94010.